Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TEMPE, Ariz., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), today will hold a conference call and webcast to provide a quarterly Company update. Conference...
-
TEMPE, Ariz., Aug. 19, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) (the "Company") will host a conference call and webcast on Tuesday, August 23, 2011 at 1:00 pm EDT / 10:00 am PDT....
-
TEMPE, Ariz., July 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced results from a pre-clinical study of AZX100 in a rodent model of radiation-induced...
-
TEMPE, Ariz., June 8, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced that at its Annual Meeting held on Monday June 6, 2011, there were insufficient shares...
-
TEMPE, Ariz., May 31, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced a material transfer agreement with BiolineRx (Jerusalem) to develop Chrysalin (TP508)...
-
TEMPE, Ariz., May 26, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") reminds stockholders that its Annual Meeting is scheduled for Monday June 6, 2011 and encourages all...
-
TEMPE, Ariz., April 27, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced that the final results from its AZX100 Phase 2a pilot clinical trial in surgical...
-
TEMPE, Ariz., April 4, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced an update to the reporting schedule for twelve-month results from its AZX100 Phase...
-
TEMPE, Ariz., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Biotech Showcase 2011, Parc 55 Wyndham San Francisco – Union Square,...
-
TEMPE, Ariz., Dec. 13, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid...